CN Bio PhysioMimix Organ-on-a-Chip data supports Inipharm’s INI-822 for metabolic liver disease treatment now in clinical testing Post author: Post published: December 4, 2023 Post category:uncategorized CN Bio today announced its PhysioMimix® assay for Non-alcoholic steatohepatitis (NASH). You Might Also Like Study probes the hidden impact of low-cal sweeteners on gut health November 5, 2023 Understanding the trends of various neurological disorders in the Chinese population January 19, 2026 Intimate relationships may shield against cognitive decline during chemo April 29, 2025
Understanding the trends of various neurological disorders in the Chinese population January 19, 2026